DDInter1070 DDInter899
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Linagliptin {u} (Compound) resembles {v} (Compound) Alogliptin
Linagliptin {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Linagliptin {u} (Compound) binds {v} (Gene) CYP3A4
Linagliptin {u} (Compound) is included by {v} (Pharmacologic Class) Dipeptidyl Peptidase 4 Inhibitors
Linagliptin {u} (Compound) causes {v} (Side Effect) Upper respiratory tract infection
Linagliptin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Linagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Linagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metamfetamine
Linagliptin {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Linagliptin (Compound) resembles Alogliptin (Compound)
Linagliptin (Compound) treats type 2 diabetes mellitus (Disease)
Linagliptin (Compound) binds CYP3A4 (Gene)
Linagliptin (Compound) is included by Dipeptidyl Peptidase 4 Inhibitors (Pharmacologic Class)
Linagliptin (Compound) causes Upper respiratory tract infection (Side Effect)
Linagliptin may cause a minor interaction that can limit clinical effects when taken with Amcinonide
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine
Linagliptin may lead to a major life threatening interaction when taken with Bexarotene